US-based Onspira Therapeutics has announced that its OSP-101, an inhaled interleukin-1 receptor antagonist (IL-1Ra) for the treatment of bronchiolitis obliterans, has been granted orphan drug designation by the FDA. Onspira is a private company created by NeXeption in 2017, and OSP-101 is currently its only candidate.
Onspira Therapeutics President and CEO Brian Lortie said, “We are very pleased that FDA granted Orphan Drug Designation to OSP-101 for the treatment of bronchiolitis obliterans (BO). This is a significant milestone for Onspira, and we look forward to advancing the clinical program in coordination with the FDA and our advisors. BO is a relentless, progressive disease which causes significant mortality in affected patients, and our team is highly focused on providing an effective therapy to improve their lives.”
Lung Transplant Foundation President Jeffrey Goldstein commented, “Advancing the development of novel approaches to the treatment of this terrible condition is a key priority of the Lung Transplant Foundation. We are proud to have played a part in achieving this milestone and look forward to the further development of OSP-101.” According to the Lung Transplant Foundation website, the organization funds research into bronchiolitis obliterans, but no details are provided.
Read the Onspira Therapeutics press release.
